Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 221Colorectal Neoplasms 196Rectal Neoplasms 174Stomach Neoplasms 116Pancreatic Neoplasms 100Neoplasm Metastasis 77Colonic Neoplasms 59Neoplasms 50Esophageal Neoplasms 39Triple Negative Breast Neoplasms 38Nasopharyngeal Carcinoma 28Biliary Tract Neoplasms 27Cholangiocarcinoma 22Gallbladder Neoplasms 20Locally Advanced Rectal Cancer 17Carcinoma, Hepatocellular 17Adenocarcinoma 15Gastrointestinal Neoplasms 13Colorectal Cancer Metastatic 13Head and Neck Neoplasms 12Bile Duct Neoplasms 12Adenocarcinoma Of Esophagus 12Esophageal Squamous Cell Carcinoma 11Breast Neoplasms, Male 11Brain Neoplasms 11Liver Neoplasms 10Carcinoma, Renal Cell 10Neuroendocrine Tumors 9Unspecified Adult Solid Tumor, Protocol Specific 8Squamous Cell Carcinoma of Head and Neck 8

Interventions

Everolimus 5Cetuximab 2volagidemab 1tanezumab 1pembrolizumab 1inavolisib 1Vemurafenib 1Trimetazidine 1Sirolimus 1Secretin 1SF 1126 1Pharmaceutical Preparations 1Panobinostat 1Oxaliplatin 1Nivolumab 1NVP-BKM120 1Leucovorin 1Irinotecan 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Alpelisib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hereditary Sensory and Autonomic Neuropathies × Capecitabine × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡